What are the typical clinical features, diagnostic work‑up, and first‑line disease‑modifying antirheumatic drug regimen for rheumatoid arthritis in adults?

Rheumatoid Arthritis: Clinical Features, Diagnostic Work-Up, and First-Line Treatment

Clinical Features

Rheumatoid arthritis typically presents with symmetric polyarthritis affecting small joints, particularly the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, accompanied by morning stiffness lasting at least 1 hour. 1

Key Presenting Symptoms

• Symmetric joint swelling and tenderness involving multiple small joints of the hands and feet 1, 2
• Morning stiffness exceeding 30–60 minutes that improves with activity; duration correlates with disease activity 1, 3
• Constitutional symptoms including fatigue, low-grade fever, weight loss, and malaise 1, 4
• Insidious onset in approximately 75% of patients, though 25% present with acute or subacute symptoms 1

Joint Distribution Patterns

• Commonly affected: wrists, metacarpophalangeal joints, proximal interphalangeal joints, metatarsophalangeal joints, and knees 1
• Characteristically spared: distal interphalangeal joints, sacroiliac joints, and lumbar spine 1
• Any synovial joint can be involved, including the cricoarytenoid joint 1

Extra-Articular Manifestations

• Rheumatoid nodules, vasculitis, hematologic abnormalities, Felty's syndrome, and visceral involvement may occur 1, 3

---

Diagnostic Work-Up

The diagnosis requires at least one joint with definite swelling not explained by another disease, with the likelihood increasing as more small joints are involved. 2

Essential Laboratory Tests at Baseline

• Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies: high specificity (90%) for RA; anti-CCP has moderate sensitivity (60%) 3, 2, 5
• Inflammatory markers: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); CRP correlates with clinical assessment and radiographic changes 1, 3
• Complete blood count with differential to assess for anemia and leukocytosis 2, 6
• Hepatic function tests (transaminases) and renal function tests (creatinine, eGFR) before initiating DMARDs 2, 6

Imaging Studies

• Plain radiographs of hands and feet at baseline to detect early erosions, soft tissue swelling, and juxtaarticular osteoporosis 1, 6
• Ultrasonography can detect synovial thickening even in finger joints when clinical assessment is uncertain 1, 5

Pre-Treatment Safety Screening

• Tuberculosis screening (tuberculin skin test or interferon-gamma release assay) is mandatory before starting biologic DMARDs or JAK inhibitors 7, 2, 6
• Hepatitis B and C testing for patients being considered for biologic agents 2

---

First-Line Disease-Modifying Antirheumatic Drug Regimen

Methotrexate 15–25 mg orally once weekly with folic acid supplementation should be started immediately upon diagnosis, rapidly escalating to 25–30 mg weekly within 4–6 weeks, combined with short-term low-dose glucocorticoids (≤10 mg/day prednisone-equivalent) for up to 6 months as bridging therapy. 7, 6

Methotrexate: The Anchor DMARD

• Methotrexate is the first-line treatment for all patients with active RA unless contraindicated 7
• Start at 15–25 mg weekly with mandatory folic acid 1 mg daily to reduce adverse effects 6, 5
• Rapidly escalate to 20–25 mg weekly within a few weeks; this is the optimal dose in Western populations 6, 8
• If oral methotrexate is not tolerated or ineffective, switch to subcutaneous administration before declaring treatment failure 6, 5
• Maintain the maximal dose for at least 3 months before assessing efficacy 5

Glucocorticoid Bridge Therapy

• Add low-dose prednisone ≤10 mg/day (or equivalent) at treatment initiation for rapid symptom control while methotrexate takes effect (typically 6–12 weeks) 7, 6, 7
• Limit glucocorticoid exposure to less than 3 months and taper as rapidly as clinically feasible 7, 6, 5
• Prolonged use beyond 1–2 years markedly increases risks of osteoporosis, fractures, cataracts, and cardiovascular disease 6, 5

Alternative First-Line Options

• When methotrexate is contraindicated or not tolerated early, leflunomide or sulfasalazine should be used as first-line alternatives 7, 6
• Hydroxychloroquine alone is inadequate for moderate-to-high disease activity due to weak disease-modifying effects 5

---

Treatment Targets and Monitoring

The primary therapeutic goal is sustained clinical remission, defined by SDAI ≤3.3, CDAI ≤2.8, or ACR-EULAR Boolean criteria (≤1 tender joint, ≤1 swollen joint, CRP ≤1 mg/dL, patient global ≤1/10); low disease activity (SDAI ≤11 or CDAI ≤10) is an acceptable alternative when remission cannot be achieved. 7, 6

Monitoring Schedule

• Assess disease activity every 1–3 months during active disease using composite measures: tender/swollen joint counts, patient and physician global assessments, ESR or CRP 7, 6
• Expect ≥50% improvement within the first 3 months of therapy; failure to reach this threshold mandates immediate escalation 7, 6, 5
• The treatment target must be reached within 6 months; if not, therapy should be escalated or modified 7, 6

Laboratory Monitoring for Methotrexate

• First 3 months: complete blood count, liver transaminases, and serum creatinine every 2–4 weeks 7
• 3–6 months: every 8–12 weeks 7
• Beyond 6 months: every 12 weeks 7

---

Treatment Escalation Strategy

For Patients Without Poor Prognostic Factors

• Switch to another conventional DMARD or add triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) if inadequate response at 3 months 7, 6, 5

For Patients With Poor Prognostic Factors

Poor prognostic factors include: high RF or anti-CCP titers, high baseline disease activity (DAS28 >5.1), early erosive changes, or failure of two conventional DMARDs 7, 6

• Add a biologic DMARD or JAK inhibitor to methotrexate if inadequate response persists after 3–6 months of optimized conventional DMARD therapy 7, 6
• TNF-α inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab) are the preferred first-line biologic agents 7, 5
• Alternative biologic classes: IL-6 receptor antagonists (tocilizumab, sarilumab), T-cell costimulation modulators (abatacept), or rituximab (particularly for seropositive patients) 7, 5
• JAK inhibitors (tofacitinib, baricitinib) are appropriate when biologics are unsuitable or after biologic failure; tofacitinib showed superior efficacy versus placebo (ACR20 response OR 2.44) and versus methotrexate (OR 2.38) 7

---

Critical Pitfalls to Avoid

• Do not delay DMARD initiation while awaiting specific serologic thresholds; treatment should start at diagnosis because delays lead to irreversible joint damage 7, 6, 8
• Do not underdose methotrexate; escalation to 20–25 mg weekly is required before declaring treatment failure 6, 5
• Do not rely on NSAIDs or corticosteroids alone; they provide only symptomatic relief without disease modification 6, 5, 4
• Do not continue ineffective therapy beyond 3–6 months without escalation; ongoing joint damage becomes irreversible 7, 6, 5
• Do not use DAS28 <2.6 as the remission target; adopt ACR-EULAR remission criteria instead 6